Published in Health Business Week, December 8th, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at BioMimetic Therapeutics.
Report 1: BioMimetic Therapeutics, Inc., (BMTI) announced that William V. Giannobile, DDS, DMSc, provided 12 and 24 month follow-up results from the pivotal clinical trial for the company's lead product, GEM 21S Growth-factor Enhance Matrix, for the treatment of periodontal disease and gingival recession.
The data demonstrate continued long-term efficacy for GEM 21S treatment, with improved bone growth observed throughout the 24 month...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.